Skip to main content

Advertisement

SpringerLink
Log in

The inhibition of angiogenesis by antisense oligonucleotides to clusterin

  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

Angiogenesis is a primary disease target in ocular retinopathy and a secondary target in numerous other angiogenic diseases such as cancer, rheumatoid arthritis and psoriasis. Clinical trials using antiangiogenic antisense oligonucleotides (aso’s) for the treatment of ocular disorders or cancer are well advanced. Clusterin aso’s are currently under investigation for the treatment of prostate cancer. We have investigated the antiangiogenic properties of clusterin aso’s using a capillary cell (HUVEC) viability assay. In this study we included aso’s to known apoptosis modulators (bcl-2, bcl-xl and survivin) which were previously identified in HUVEC’s. We have also studied the effect of clusterin aso’s on angiogenesis using an in vitro, matrigel assay and on HUVEC apoptosis using an ELISA DNA fragmentation assay. Clusterin, bcl-2, bcl-xl and survivin aso’s were all found to inhibit HUVEC growth. The apoptosis-inducing drugs paclitaxel, camptothecin and doxorubicin were also found to inhibit HUVEC proliferation. Combinations of aso’s with these drugs demonstrated a minor additive but not synergistic inhibitory effect on HUVEC proliferation. Clusterin aso’s were found to strongly inhibit angiogenesis and induce high levels of apoptosis in HUVECs. In cancer cells the prosurvival protein clusterin may protect the cells from apoptosis-inducing agents so that the clusterin aso’s may act as chemosensitization agents. These data demonstrate a strong antiangiogenic action of clusterin aso’s, that is not necessarily related to any chemosensitization effect of this agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stahel RA, Zangemeister-Witte U. (2003). Antisense oligonucleotides for cancer therapy – an overview. Lung Cancer 41:581–588

    Article  Google Scholar 

  2. El-Aneed A. (2004). Current strategies in cancer therapy. European Journal of Pharmacology 498:1–8

    Article  PubMed  CAS  Google Scholar 

  3. Gleave ME, Miyake H, Zellweger T et al. (2001). Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 58(2 Suppl 1):39–49

    Article  PubMed  CAS  Google Scholar 

  4. Zellweger T, Miyake H, July LV. (2001). Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3(4): 360–7

    Article  PubMed  CAS  Google Scholar 

  5. Miyake H, Hara I, Kamidono S et al. (2001). Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligonucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7(12):4245–4252

    PubMed  CAS  Google Scholar 

  6. Zellweger T, Miyake H, July LV et al. (2001). Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2’-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298(3): 934–40

    PubMed  CAS  Google Scholar 

  7. Del Bufalo D, Trisciuciuoglio D, Scarsella M, Zangemeister-Witte U, Zupi G. (2003). Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 22:8441–8447

    Article  PubMed  CAS  Google Scholar 

  8. Henry SP, Marcusson EG, Vincent TM, Dean NM. (2004). Settings sights on the treatment of ocular angiogenesis using antisense oligonucleotides. Trends in Pharmacological Sciences 25(10):523–527

    Article  PubMed  CAS  Google Scholar 

  9. Bhisitkul RB, Robinson GS, Moulton RS, Claffey KP, Gragoudas ES, Millar MD. (2005). Arch. Ophthalmol 123(2): 214–219

    Article  PubMed  CAS  Google Scholar 

  10. Marano RJ, Rakoczy PE. (2005). Treatments for choroidal and retinal neovascularization: a focus on oligonucleotide therapy and delivery for the regulation of gene function. Clinical and Experimental Ophthamology 33:81–89

    Article  Google Scholar 

  11. Kim B, Tang Q, Biswas PS, Schifflers RM, Xie FY, Ansari AM, Scaria PV, Woodle MC, Lu P, Rouse BT. (2004). Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165(6):2177–2185

    PubMed  CAS  Google Scholar 

  12. Blaschuk O, Burdzy K, Fritz IB. (1983). Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 12:7714–7720

    Google Scholar 

  13. Rosenberg ME, Silkensen J. (1995). Clusterin: Physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 27(7):633–645

    Article  PubMed  CAS  Google Scholar 

  14. July LV, Akbari M, Zellweger T et al. (2002). Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. The Prostate 50:179–188

    Article  PubMed  CAS  Google Scholar 

  15. Gleave ME, Zellweger T, Chi K et al. (2002). Targeting anti-apoptotic genes upregulated by androgen withdrawl using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 20(2):145–58

    Article  CAS  Google Scholar 

  16. Redondo M, Villar E, Torres-Munoz J et al. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000; 157(2): 393–9

    Google Scholar 

  17. Lee C, Janulis L, Ilio K et al. (2000). In vitro models of prostate apoptosis: clusterin as an antiapoptotic mediator. Prostate Suppl 9:21–4

    Article  PubMed  CAS  Google Scholar 

  18. Cervellera M, Raschella G, Santilli G et al. (2000). Direct transactivation of the anti-apoptotic gene apopliprotein J (clusterin) by B-MYB. J Biol Chem 275(28):21055–60

    Article  PubMed  CAS  Google Scholar 

  19. Viard I, Wherli P, Jornot L et al. (1999). Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Invest Dermatol 112(3):290–6

    Article  PubMed  CAS  Google Scholar 

  20. Artwohl M, Holzenbeinn T, Wagner L, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM. (2000). Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol 131(8):1577–1583

    Article  PubMed  CAS  Google Scholar 

  21. McLaughlin L, Zhu G, Mistry M, Ley-Ebert C, Stuart WD, Florio CJ, Groen PA, Witt SA, Kimball TR, Witte DP, Harmony JAK, Aronow BJ. (2000). Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J. Clin. Invest. 106(9):1105–1113

    Article  PubMed  CAS  Google Scholar 

  22. Swertfeger DK, Witte DP, Stuart WD, Rockman HA, Harmony JA. (1996). Apolipoprotein J/clusterin induction in myocarditis: A localized response gene to myocardial injury. Am. J. Pathol. 148:1971–1983

    PubMed  CAS  Google Scholar 

  23. Pollman MJ, Naumovski L, Gibbons GH. (1999). Endothelial cell apoptosis in capillary network remodeling. Journal of Cellular Physiology 178: 359–370

    Article  PubMed  CAS  Google Scholar 

  24. Noe V, Lavarino C, Adan J, Rivas M, Lopez-Matas M, Pagan R, Mitjans F, Vilaro S, Piulats J, Ciudad CJ. (2004). Use of siRNAs and antisense oligonucleotides against surviving RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides 14 (2):100–113

    Article  PubMed  CAS  Google Scholar 

  25. 25. Hida A, Kawakami A, Miyashita T, Yamasaki S, Nakashima K, Tanaka F, Izumi Y, Tamai M, Huang M, Ida H, Nakamura H, Origuchi T, Ueki Y, Eguchi K. (2004). Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis. J. Lab. Clin. Med. 144:148–155

    Article  PubMed  CAS  Google Scholar 

  26. Fontanini G, Boldrini L, Vignati S, Chine S, Basolo F, Silvestri V, Lucch M, Mussi A, Angeletti CA, Bevilacqua G. (1998). Bcl2 and p53 regulate vascular endothelial growth factor (VEGF) mediated angiogenesis in non-small cell lung carcinoma. Eur J. Cancer 34(5):718–723

    Article  PubMed  CAS  Google Scholar 

  27. Leech SH, Olie RA, Gautschi O. (2000). Induction of apoptosis in lung cancer cells flowing bcl-xl antisense treatment. Int. J. Cancer. 86:570–576

    Article  PubMed  CAS  Google Scholar 

  28. Simoes-Wust A, Schurpf T, Hall J, Stahel RA, Zangemeister-Witte U. (2002). Bcl-2/bcl-xl bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 76:157–166

    Article  PubMed  Google Scholar 

  29. Ackermann EJ, Taylor JK, Narayama R, Bennett CF. (1999). The role of antiapoptotic bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J. Biol. Chem. 274(16):11245–11252

    Article  PubMed  CAS  Google Scholar 

  30. 30. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. (1999). Induction of endogenous bcl-xs through the control of bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17:1097–1100

    Article  PubMed  CAS  Google Scholar 

  31. Miyake H, Monia BP, Gleave ME. (2000). Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense bcl-xl and antisense bcl-2 oligonucleotides plus taxol after castration in the Shinogi tumor model. Int. J. Cancer. 86:855–862

    Article  PubMed  CAS  Google Scholar 

  32. Sivamurthy N, Stone DH, Logerfo FW, Quist WC. (2001). Apolipoprotien J inhibits the migration and adhesion of endothelial cells. Surgery 130:204–209

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors would like to thank Oncogenex Technologies, Vancouver. B.C. Canada for funds that helped support this work.

Author information

Authors and Affiliations

  1. Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada

    John K. Jackson, Jacqueline Gleave & Helen M. Burt

  2. The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada

    Martin E. Gleave

Authors
  1. John K. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin E. Gleave
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacqueline Gleave
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helen M. Burt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helen M. Burt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jackson, J.K., Gleave, M.E., Gleave, J. et al. The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis 8, 229–238 (2005). https://doi.org/10.1007/s10456-005-9018-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10456-005-9018-5

Keywords

Search

Navigation